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ABSTRACT
Objective: There is a need for an early detection of carbapenemase-producing Gram-negative bacilli to reduce the morbidity and mortality associated 
with it. The objective of this study is to evaluate the usefulness of the Carba NP test in detecting carbapenemase-producing Gram-negative bacilli.
Methods: This prospective experimental study was conducted in 2013 at PSG Institute of Medical Sciences and Research, Coimbatore. In this study, 
120 consecutive Gram-negative bacilli clinical isolates identified as carbapenem resistant as per the Clinical and Laboratory Standard Institute 
guidelines were subjected to Carba NP.
Results: About 62.5% of the carbapenem-resistant isolates were found to be carbapenemase producers by modified Hodge test. The sensitivity of 
the Carba NP test was found to be 92% and the specificity was 100%. The most common bacterial isolate was Acinetobacter baumannii, and the most 
common sample was urine.
Conclusion: The Carba NP test is a simple inexpensive, rapid, reproducible, sensitive test that can be performed directly from the colonies. It improves 
early detection of patients infected or colonized with carbapenemase in the hospital.
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INTRODUCTION
Carbapenem-resistant Gram-negative bacilli have emerged and are 
being reported globally at increasing rates. Carbapenem sensitivity of 
Pseudomonas aeruginosa strains isolated from patients with urinary 
tract infection was only 37% in a study conducted in South India [1]. 
With limited treatment options and the high morbidity and mortality 
associated with infections caused by them, it is a huge concern 
requiring immediate scientific attention. Carbapenem resistance due to 
non-carbapenemase-mediated mechanisms includes outer membrane 
permeability defect, efflux mechanisms, loss of porins associated 
with overproduction of cephalosporinase, and/or extended-spectrum 
β-lactamases or from strains that are carbapenem susceptible but 
express a broad-spectrum β-lactamase without carbapenemase activity, 
extended-spectrum β-lactamase, and plasmid- and chromosome-
encoded cephalosporinases [2]. Carbapenemase production is coded on 
plasmids and transferred from one bacterium to the other very easily. 
There is a need for an early detection of carbapenemase-producing 
Gram-negative bacilli and isolate patients harboring them and treat 
them effectively. The currently used Clinical and Laboratory Standard 
Institute (CLSI) recommended modified Hodge test (MHT) for the 
detection of carbapenemase takes 18-24 h [3]. To detect carbapenemase 
production, Carba NP test was developed by Nordmann et al. based on 
the principle of hydrolysis of carbapenem [4].
MATERIALS AND METHODS
Materials
After obtaining an Institutional Human Ethics Committee approval, 
this prospective experimental study was conducted at PSG Institute of 
Medical Sciences and Research, Coimbatore, over a period of 6 months 
in 2013 on 120 consecutive Gram-negative isolates identified as 
carbapenem-resistant by MHT as per the CLSI-2013 guidelines out of 
2590 Gram-negative bacilli isolates obtained from a range of samples 
which included urine, pus, blood, sputum, tracheal aspirate, catheter 
tip, tissue, and body fluids. Carbapenemase production of these isolates 
was detected by subjecting them to MHT and Carba NP test.
Methods
MHT
A 0.5 McFarland dilution of the Escherichia coli ATCC 25922 in 5 ml of 
Mueller-Hinton (MH) broth was prepared. Lawn culture was made on 
the MH agar plate with 1:10 dilution of this solution, and a meropenem 
disc (30 µg) was placed in the center. In a straight line, test organism 
was streaked from the edge of the disk to the edge of the plate and was 
incubated at 37°C for 16–24 h. Clover leaf-like indentation of the E. coli 
25922 along the streak of the test organism growth within the diffusion 
zone of the disk was identified as positive [3].
Carba NP test
This test was performed on strains grown on MH agar plates at 37°C 
for 18–22 h. One calibrated loop (10 μl) of the tested strain directly 
obtained from the MH agar plate was re-suspended in100 μl of a 20 mM 
Tris-HCl lysis buffer vortexed for 1 min and was further incubated 
at room temperature for 30 min. This bacterial suspension was then 
centrifuged at 10,000 rpm at room temperature for 5 min. Thirty 
microliters of the supernatant was mixed in a well of a 96-well tray 
with 100 μl of imipenem monohydrate (3 mg/ml) solution, phenol red 
solution, and 0.1 mM ZnSO4 and was incubated at 37°C for a maximum 
of 2 h. Change in color from red to orange or yellow was interpreted as 
positive and no change in color as negative [4].
RESULTS
In our study, 120 (4.63%) isolates were found to be carbapenem 
resistant, of the 2590 Gram-negative bacilli isolated from various 
clinical samples. Urine was the predominant sample 47% (56), followed 
by respiratory samples (27), pus sample (26), blood (8), and others 
(3). Of the 120 samples included in the study, Acinetobacter baumannii 
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was the predominant organism 47.5% (57), followed by Klebsiella 
pneumoniae (29), P. aeruginosa (21), E. coli (8), Enterobacter sp. (3), 
Proteus sp. (1), and Citrobacter sp. (1) as mentioned in Table 1.
We found that 62.5% (75) of the isolates were positive by MHT. The 
sensitivity of the Carba NP test was found to be 92% (69), and the 
specificity was 100% (Table 2). The positive predictive value of Carba 
NP test was 100%, and the negative predictive value was 88.24%.
DISCUSSION
Carbapenems, the last-line drug of therapy, are increasingly reported 
to be resistant to Gram-negative bacilli causing severe infections. 
Early detection of these organisms is important to initiate appropriate 
therapy and for the implementation of infection control practices. In 
our study, we found 62.5% of the carbapenem-resistant organism as 
carbapenemase producers by MHT. Other isolates might be carbapenem 
resistance due to non-carbapenemase-mediated mechanisms. 
Among many mechanisms of carbapenem resistance, carbapenemase 
production is the most important one.
The sensitivity and specificity of the Carba NP test were described to 
be 100% by Dordet Poirel and Nordmann et al. However, in our study, 
we found the sensitivity to be low (92%). Similar to results in our 
study, evaluation of Rapidec Carba NP test, a commercially available 
test for detection of carbapenemases in Enterobacteriaceae derived 
from the Carba NP-I assay, had sensitivity and specificity of 90.2% 
and 100%, respectively, when strictly followed the manufacturer’s 
instructions [5]. In our study, the type of carbapenemase produced 
was not studied. Carba NP test II developed by Dortet et al. enabled to 
identify carbapenemase production in Gram-negative bacilli and also 
to discriminate between the different types of carbapenemases. It is 
based on the detection of the acidification resulting from imipenem 
hydrolysis, coupled with tazobactam and ethylenediaminetetraacetic 
acid (EDTA) as inhibitors [6]. In our study, 3 mg/ml concentration 
of imipenem and supernatant obtained after centrifuging the lysed 
bacterial cells was used for the final reaction. Vasoo et al. utilized whole 
bacterial cells instead of supernatant obtained from bacterial lysis 
and an increased concentration of imipenem (6 instead of 3 mg/ml) 
and found that their approach enabled detection of carbapenemase-
producing Pseudomonas species isolates which were initially negative 
when tested with 3 mg/ml of imipenem and supernatant obtained after 
bacterial lysis [7]. Apart from the use of supernatant and an increased 
concentration of imipenem, sensitivity of the test can be affected 
by extraction process, expression of gene, hydrolyzing ability of the 
carbapenemase, stability of carbapenem, inhibitors present, and the pH 
of the solution. Of 36 isolates of carbapenemase-producing A. baumanii, 
only 33 isolates were detected as carbapenemase producers by Carba 
NP test in our study. A modified version of Carba NP test and CarbAcineto 
test, was developed by Dortet et al. to enhance the detection rates of 
carbapenemase-producing Acinetobacter species by replacing the lysis 
buffer by a 5 M NaCl solution, avoiding any buffer effect, and doubling 
the bacterial inoculum from one-third to one-half of a calibrated loop 
(10 µl) to a whole calibrated loop to increase the enzyme quantity [8].
The huge advantage of Carba NP test is that the interpretable positive 
results were obtained in <2 h, making it possible to implement rapid 
containment measures to limit the spread of carbapenemase producers. 
Carba NP test may be useful in particular for intensive care unit and burns 
patients, among whom multidrug-resistant isolates are widespread. It 
offers a cost-effective solution for detecting carbapenemase-producing 
Gram-negative bacilli and preventing their spread, considering that 
they may harbor those carbapenemase producing genes on plasmids 
that can spread to other bacterial families (Enterobacteriaceae and the 
family that includes Acinetobacter species). The limitation of the study 
is that molecular diagnosis of carbapenemase producer and typing of 
carbapenemases were not included in the study. Combination therapy 
is recommended for carbapenem-resistant Gram-negative organisms. 
However, colistin-carbapenem combination therapy has been observed 
to have low clinical success rate probably due to indifferent interactions 
between them [9].
CONCLUSION
Including this sensitive and rapid test in routine evaluation of the 
bacterial isolates can initiate prompt treatment and aggressive infection 
control measures to prevent its spread in the health-care facility.
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MHT test +VE Carba NP test +VE
A. baumannii 57 36 33
K. pneumoniae 29 19 18
P. aeruginosa 21 12 11
E. coli 8 5 5
Enterobacter sp. 3 2 1
Proteus sp. 1 1 1
Citrobacter sp. 1 - -
Total 120 75 69
A. baumannii: Acinetobacter baumannii, K. pneumoniae: Klebsiella pneumoniae, 
P. aeruginosa: Pseudomonas aeruginosa, E. coli: Escherichia coli, MHT: Modified 
Hodge test
Table 2: Comparison of MHT and Carba NP test in detecting 
carbapenemases
Carba NP test (+) Carba NP test (-) Total
MHT (+) 69 6 75
MHT (-) 0 45 45
Total 69 51 120
MHT: Modified Hodge test
